Champions Oncology Announces its Lumin Bioinformatics Platform Selected as a Finalist for the 'Best in Show' Competition at Bio-IT World Conference & Expo
Champions Oncology, Inc. (NASDAQ:CSBR) announced its Lumin Bioinformatics Platform has been selected as a finalist for the 'Best in Show' Competition at the Bio-IT World Conference & Expo.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Champions Oncology, Inc. (NASDAQ:CSBR) announced its Lumin Bioinformatics Platform has been selected as a finalist for the 'Best in Show' Competition at the Bio-IT World Conference & Expo. The demonstration will take place on May 4th. Lumin is a powerful tool that provides access to over 2 billion data points from more than 12,000 cancer patients, enabling advanced analytics and integration of user data. CEO Ronnie Morris emphasized the platform's evolving capabilities and its role in transforming cancer research and biomarker discovery.
Positive
- Lumin Bioinformatics Platform selected as a finalist for the 'Best in Show' Competition, showcasing industry recognition.
- Platform provides access to extensive data from over 12,000 cancer patients, enhancing research capabilities.
- Recent updates include UI/UX improvements and new analysis modules, expanding functional capabilities.
Negative
- None.
Details
News Market Reaction – CSBR
The recorded move for CSBR in the trading session of this news was -1.05%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HACKENSACK, NJ / ACCESSWIRE / May 3, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, announced today that its Lumin Bioinformatics Platform has been selected as a finalist for the ‘Best in Show' Competition at the upcoming Bio-IT World Conference & Expo. The company will present an overview and live demonstration of the platform to judges on May 4th.
Lumin Bioinformatics is a dynamic analysis and visualization platform that empowers biologists and bioinformaticians to harness the power of computational science in a convenient and sophisticated tool. By offering over 2 billion data points to drive biological hypothesis, Lumin allows users to explore and perform analyses on rich and unique multi-omic datasets from over 12,000 cancer patients, including thousands of clinical treatment responses not available in any public dataset, and access to publicly available cancer datasets in a standardized format. Continuously expanding multi-omics datasets, including Next Generation Sequencing (WES and RNASeq), quantitative proteomics, and phospho-proteomics, are the backbone of the Lumin Analytic Engine. Lumin offers access to advanced analytics and AI using predictive and interactive gene networks, the ability to explore correlative and causal relationships to generate biomarker signatures while allowing the user to integrate their own data, analyses, and code with pre-built code and visualization.
Ronnie Morris, MD, President and CEO of Champions Oncology, said "This is a great moment for Champions. It is exciting to see the external validation of the value that this platform brings to users. The Lumin platform continues to evolve, and with each day, changes the way we understand tumor cell biology and approach research efforts, including target and biomarker discovery. We see the tools and workflows available in Lumin driving a transformation towards a more integrative approach to cancer research".
"We are thrilled to be selected as a finalist in this competition", said Michael Ritchie, PhD, MBA, Chief Commercial Officer at Champions. "It has been incredible to see the rapid and transformative growth of what is available in Lumin. Our latest release of Lumin Bioinformatics included UI/UX feature upgrades and the addition of large amounts of proprietary PDX proteomics datasets. The latest release also includes our new ex-vivo analysis module offering to incorporate data from ex-vivo experiments for further analysis, such as differential gene expression between responders and non-responders."
About Champions Oncology
Champions Oncology is a technology-driven research organization that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R&D services to biopharma organizations. Champions Oncology is actively engaged in the transformation of drug discovery through a novel approach of pharmaco-pheno-multiomic integration. For more information, please visit www.ChampionsOncology.com.
Media Contact:
Rachel Bunting, MS, MBA
Sr. Director, Head of Marketing
Marketing@ChampionsOncology.com
Website: www.championsoncology.com
Facebook: https://www.facebook.com/championsoncology/
LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
Twitter: https://twitter.com/ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/
SOURCE: Champions Oncology, Inc.
View source version on accesswire.com:
https://www.accesswire.com/699790/Champions-Oncology-Announces-its-Lumin-Bioinformatics-Platform-Selected-as-a-Finalist-for-the-Best-in-Show-Competition-at-Bio-IT-World-Conference-Expo
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.